HSCS (HeartSciences) Beginning Cash Position: $1.95 Mil (As of Jan. 2026)


HSCS HeartSciences Inc HSCS
48 GF Score
Price $2.75
GF Value $2.59
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is HeartSciences Beginning Cash Position?

HeartSciences HSCS +0.74% 48 Beginning Cash Position is $1.95 Mil as of Jan. 2026. GuruFocus rates HSCS with a GF Score™ of 48/100 and a GF Value™ of $2.59 (Fairly Valued). The stock has 7 warning signs investors should review.

HeartSciences's Beginning Cash Position for the quarter that ended in Jan. 2026 was $1.95 Mil.

HeartSciences's quarterly Beginning Cash Position increased from Jul. 2025 ($1.10 Mil) to Oct. 2025 ($2.79 Mil) but then declined from Oct. 2025 ($2.79 Mil) to Jan. 2026 ($1.95 Mil).

HeartSciences's annual Beginning Cash Position increased from Apr. 2023 ($0.92 Mil) to Apr. 2024 ($1.66 Mil) and increased from Apr. 2024 ($1.66 Mil) to Apr. 2025 ($5.81 Mil).

HeartSciences Beginning Cash Position Related Terms

HeartSciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for HeartSciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeartSciences Beginning Cash Position Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Beginning Cash Position
Get a 7-Day Free Trial 0.50 0.72 0.92 1.66 5.81

HeartSciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 2.60 1.10 2.79 1.95
HSCS
48GF Score
HeartSciences Inc HSCS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeartSciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1.95 Mil mean?
HeartSciences (HSCS) has a Beginning Cash Position of $1.95 Mil as of Jan. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on HeartSciences and its competitors.
Is HeartSciences' Beginning Cash Position too high?
HeartSciences' current Beginning Cash Position is $1.95 Mil. Overall, HeartSciences has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' Beginning Cash Position compare to CSDX and CODX?
HeartSciences' Beginning Cash Position of $1.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on HeartSciences and its competitors. HeartSciences's current Beginning Cash Position is $1.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
Based on GuruFocus' analysis, HeartSciences (HSCS) is currently considered Fairly Valued. The stock's GF Value™ is $2.59, compared to a current price of $2.75 — trading 6.2% above its estimated fair value. The current Beginning Cash Position is $1.95 Mil. HeartSciences' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For HeartSciences (HSCS), the current Beginning Cash Position is $1.95 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.75 is trading 6.2% above its estimated GF Value™ of $2.59. GuruFocus considers HeartSciences to be Fairly Valued.

Key valuation signals for HSCS:

  • Beginning Cash Position: $1.95 Mil
  • GF Value™: $2.59 vs. price of $2.75 (6.2% above fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
48GF Score

Get the complete analysis for HSCS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price
$2.59
GF Value